Literature DB >> 17911976

Dry powder inhalers: which factors determine the frequency of handling errors?

Siegfried Wieshammer1, Jens Dreyhaupt.   

Abstract

BACKGROUND: Dry powder inhalers are often used ineffectively, resulting in a poor level of disease control.
OBJECTIVES: To determine how often essential mistakes are made in the use of Aerolizer, Discus, HandiHaler and Turbuhaler and to study the effects of age, severity of airflow obstruction and previous training in inhalational technique by medical personnel on the error rate.
METHODS: Two hundred and twenty-four newly referred outpatients (age 55.1 +/- 20 years) were asked how they had been acquainted with the inhaler and to demonstrate their inhalational technique.
RESULTS: The inhaler-specific error rates were as follows: Aerolizer 9.1%, Discus 26.7%, HandiHaler 53.1% and Turbuhaler 34.9%. Compared to Aerolizer, the odds ratio of an ineffective inhalation was higher for HandiHaler (9.82, p < 0.01) and Turbuhaler (4.84, p < 0.05). The error rate increased with age and with the severity of airway obstruction (p < 0.01). When training had been given as opposed to no training, the odds ratio of ineffective inhalation was 0.22 (p < 0.01). If Turbuhaler is used, the estimated risks range from 9.8% in an 18-year-old patient with normal lung function and previous training to 83.2% in an 80-year-old patient with moderate or severe obstruction who had not received any training.
CONCLUSIONS: Dry powder inhalers are useful in the management of younger patients with normal lung function or mild airway obstruction. In older patients with advanced chronic obstructive pulmonary disease, the risk of ineffective inhalation remains high despite training in inhalational technique. A metered-dose inhaler with a spacer might be a valuable treatment alternative in a substantial proportion of these patients. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911976     DOI: 10.1159/000109374

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  57 in total

Review 1.  Mometasone furoate in children with mild to moderate persistent asthma: a review of the evidence.

Authors:  Henry Milgrom
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

2.  Inhalation devices and patient interface: human factors.

Authors:  Stefan Leiner; David Parkins; Orest Lastow
Journal:  AAPS J       Date:  2015-01-16       Impact factor: 4.009

3.  Empowering family physicians to impart proper inhaler teaching to patients with chronic obstructive pulmonary disease and asthma.

Authors:  Janice Leung; Mohit Bhutani; Richard Leigh; Dan Pelletier; Cathy Good; Don D Sin
Journal:  Can Respir J       Date:  2015 Sep-Oct       Impact factor: 2.409

4.  Late-Onset Asthma: A Diagnostic and Management Challenge.

Authors:  Charlotte Suppli Ulrik
Journal:  Drugs Aging       Date:  2017-03       Impact factor: 3.923

Review 5.  Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations.

Authors:  Nicola Scichilone; Fulvio Braido; Federico Lavorini; Mark L Levy; Omar S Usmani
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 6.  Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.

Authors:  Vanessa M McDonald; Isabel Higgins; Peter G Gibson
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

7.  Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.

Authors:  Thomas Voshaar; Monica Spinola; Patrick Linnane; Alice Campanini; Daniel Lock; Anthony Lafratta; Mario Scuri; Barbara Ronca; Andrea S Melani
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

8.  Medication Tracking: Design and Fabrication of a Dry Powder Inhaler with Integrated Acoustic Element by 3D Printing.

Authors:  Yongquan Li; Adam Bohr; Henrik Jensen; Jukka Rantanen; Claus Cornett; Moritz Beck-Broichsitter; Johan Peter Bøtker
Journal:  Pharm Res       Date:  2020-01-21       Impact factor: 4.200

Review 9.  Newer treatments in the management of pediatric asthma.

Authors:  Paul D Robinson; Peter Van Asperen
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

10.  Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations.

Authors:  Gabriele Nicolini; Nicola Scichilone; Andrea Bizzi; Alberto Papi; Leonardo M Fabbri
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.